TY - JOUR
T1 - The role of the microbiome in NAFLD and NASH
AU - Kolodziejczyk, Aleksandra A.
AU - Zheng, Danping
AU - Shibolet, Oren
AU - Elinav, Eran
N1 - We thank the Elinav lab for fruitful discussions and apologize to those authors whose works could not be cited due to space limitations. AAK received funding from EMBO Long Term Fellowship 2016‐1088 and the European Union's Horizon 2020 research and innovation programme under the Marie Sk?odowska‐Curie Grant Agreement No. 747114. DPZ is the recipient of the European Crohn's and Colitis Organization (ECCO) Fellowship, and is supported by the Ke Lin Program of the First Affiliated Hospital, Sun Yat‐sen University. O.S is supported by a research grant from the Alexander Grass foundation. E.E. is a senior fellow, Canadian Institute of Advanced Research (CIFAR) and an international scholar, The Bill & Melinda Gates Foundation & Howard Hughes Medical Institute (HHMI).
PY - 2019/2
Y1 - 2019/2
N2 - Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro-inflammatory and anti-inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota-derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.
AB - Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro-inflammatory and anti-inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota-derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.
KW - microbiome/microbiota
KW - nonalcoholic fatty liver disease
KW - nonalcoholic steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=85059143456&partnerID=8YFLogxK
U2 - https://doi.org/10.15252/emmm.201809302
DO - https://doi.org/10.15252/emmm.201809302
M3 - مقالة مرجعية
C2 - 30591521
SN - 1757-4676
VL - 11
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 2
M1 - e9302
ER -
